Trial Profile

Correlation of the clinical effectiveness of Erenumab, administered in a real-life setting, with changes in the expression of micro-RNA that are relevant for migraine and spinal central sensitization in subjects with chronic migraine (CM) with or without medication overuse

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 May 2020 Results evaluating role of neurophysiological, biomolecular and psychological parameters as potential predictors of the clinical outcome of Erenumab treatment in chronic migraine presented at the 6th Congress of the European Academy of Neurology
17 Jan 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com